About this medicine
- Approved name
- Ibuprofen Kabi 400 mg Infusionslösung and associated names
- International non-proprietary name (INN) or common name
- ibuprofen
- Associated names
- Ibuprofen Fresenius Kabi 400 mg oplossing voor infusie
- Ibuprofen Fresenius Kabi 400 mg solution pour perfusion
- Ibuprofen Kabi
- Ibuprofen Kabi 400 mg oldatos infúzió
- Ibuprofen Kabi 400 mg soluţie perfuzabilă
- Ibuprofen Kabi 400 mg
- Ibuprofen Kabi 400 mg raztopina za infundiranje
- Ibuprofeno Kabi 400 mg solución para perfusion
- Ibuprofen Kabi 400 mg Solution for Infusion
About this procedure
- Current status
- European Commission final decision
- Reference number
- EMEA/H/A-29(4)/1498
- Type
- Article 29(4) referrals
This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health.
- Authorisation model
- Nationally authorised product(s)
Key dates and outcomes
- CHMP opinion date
- 23/07/2020
- EC decision date
- 15/10/2020